Exploring the potential mechanisms of anti-pulmonary fibrosis effects of Luo Han Guo via network pharmacology, molecular docking, and experimental validation
8.5
来源：
Nature
关键字：
computational biology
发布时间：
2025-11-21 23:54
摘要：
This study investigates the potential mechanisms of Luo Han Guo (LHG) in treating idiopathic pulmonary fibrosis (IPF) through network pharmacology and experimental validation. It identifies key active compounds such as kaempferol and mogrol, demonstrating their roles in modulating the PI3K/AKT and SRC/STAT3 signaling pathways. The findings suggest that LHG may serve as a promising alternative treatment for IPF, addressing the need for safer and more effective therapies in managing this chronic lung disease.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分=2.0分
business_impact
0.5分+0.5分=1.0分
scientific_rigor
1.5分+1.5分=3.0分
timeliness_innovation
1.5分+1.5分=3.0分
investment_perspective
2.5分+2.5分=5.0分
market_value_relevance
1.0分+1.0分=2.0分
team_institution_background
0.5分+0.5分=0.5分
technical_barrier_competition
1.0分+1.0分=1.0分
关键证据
LHG may alleviate IPF by modulating the PI3K/AKT and SRC/STAT3 signaling pathways.
Network pharmacology identified 91 intersecting targets between LHG and IPF-related genes.
Molecular docking studies indicated strong binding affinities between LHG's active ingredients and key target proteins.
真实性检查
否
AI评分总结
This study investigates the potential mechanisms of Luo Han Guo (LHG) in treating idiopathic pulmonary fibrosis (IPF) through network pharmacology and experimental validation. It identifies key active compounds such as kaempferol and mogrol, demonstrating their roles in modulating the PI3K/AKT and SRC/STAT3 signaling pathways. The findings suggest that LHG may serve as a promising alternative treatment for IPF, addressing the need for safer and more effective therapies in managing this chronic lung disease.